Lantern Pharma gets March 24, 2027 Nasdaq deadline

Q: What is LTRN's deadline to regain Nasdaq compliance?

Lantern Pharma has until March 24, 2027, the end of a 180-calendar-day period following Nasdaq's September 25, 2026 notice, to regain compliance.

Lantern Pharma expects Nasdaq would provide a delisting notice if the company does not regain compliance by March 24, 2027.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Lantern Pharma Inc. (LTRN) received a Nasdaq notice that its common stock did not meet the $35,000,000 minimum market value of listed securities requirement after its market value stayed below that level for 30 consecutive business days. Nasdaq also said the company did not meet requirements under Listing Rules 5550(b)(1) and 5550(b)(3).

Lantern Pharma has 180 calendar days following the September 25, 2026 notice, through March 24, 2027, to regain compliance. If it seeks compliance through the market-value requirement, its market value must close at $35,000,000 or more for a minimum of 10 consecutive business days during that period. If the company does not regain compliance, it expects Nasdaq would notify it that its securities are subject to delisting from the Nasdaq Capital Market.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

0 major · 1 point

How the balance works

Positive

None.

Negative

Moderate pointNasdaq noncompliance: market value stayed below $35,000,000 for 30 consecutive business days.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Minimum market value of listed securities: $35,000,000 Days below market-value requirement: 30 consecutive business days Compliance period: 180 calendar days +2 more

5 metrics

Minimum market value of listed securities $35,000,000 Nasdaq compliance threshold

Days below market-value requirement 30 consecutive business days Market value was below $35,000,000 before the notice

Compliance period 180 calendar days Following the September 25, 2026 notice

Market-value cure test 10 consecutive business days Market value must close at $35,000,000 or more

Compliance deadline March 24, 2027 End of the compliance period

Key Terms

MVLS Requirement, Nasdaq Listing Rule 5810(c)(3)(C), subject to delisting

3 terms

MVLS Requirement market

"minimum MVLS Requirement of $35,000,000"

Nasdaq Listing Rule 5810(c)(3)(C) regulatory

"Under Nasdaq Listing Rule 5810(c)(3)(C)"

subject to delisting regulatory

"securities are subject to delisting from the Nasdaq Capital Market"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is LTRN's deadline to regain Nasdaq compliance?

Lantern Pharma has until March 24, 2027, the end of a 180-calendar-day period following Nasdaq's September 25, 2026 notice, to regain compliance.

What market value does LTRN need to regain Nasdaq compliance?

If it uses the market-value test, Lantern Pharma's market value must close at $35,000,000 or more for a minimum of 10 consecutive business days during the compliance period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/01/2026 - 04:01 PM Accepted by SEC EDGAR 10/01/2026 - 04:01 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 25, 2026

Lantern Pharma Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-39318	46-3973463
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)
1920 McKinney Avenue, 7th Floor Dallas, Texas 75201
(Address of principal executive offices)

(972) 277-1136

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b)of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value of $0.0001 per share

LTRN

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 25, 2026, Lantern Pharma Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of listed securities (the “MVLS Requirement”) for the Company’s common stock had been below the minimum MVLS Requirement of $35,000,000 for the last 30 consecutive business days. Nasdaq also noted that the Company does not meet the requirements under Listing Rules for 5550(b)(1) and 5550(b)(3).

Under Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days following the date of the notice, or until March 24, 2027, to regain compliance. To the extent the Company seeks to regain compliance through the MVLS Requirement, the Company’s market value of listed securities must close at $35,000,000 or more for a minimum of 10 consecutive business days during the 180-day compliance period. If the Company does not regain compliance within the compliance period, the Company expects that Nasdaq would provide notice that its securities are subject to delisting from the Nasdaq Capital Market.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Lantern Pharma Inc.

Dated: October 1, 2026	By:	/s/ David Margrave
		David Margrave
		Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents